$106.82
0.10% yesterday
Nasdaq, Oct 01, 10:08 pm CET
ISIN
US9250501064
Symbol
VRNA

Verona Pharma plc Sponsored ADR Stock price

$106.82
+0.91 0.86% 1M
+48.28 82.47% 6M
+60.38 130.02% YTD
+77.83 268.47% 1Y
+96.71 956.58% 3Y
+100.50 1,590.19% 5Y
+93.32 691.26% 10Y
+93.32 691.26% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
+0.11 0.10%
ISIN
US9250501064
Symbol
VRNA
Industry

Key metrics

Basic
Market capitalization
$9.2b
Enterprise Value
$9.0b
Net debt
positive
Cash
$401.4m
Shares outstanding
681.1m
Valuation (TTM | estimate)
P/E
negative | 206.1
P/S
77.3 | 21.5
EV/Sales
76.0 | 21.1
EV/FCF
negative
P/B
40.5
Financial Health
Equity Ratio
43.1%
Return on Equity
-84.8%
ROCE
-29.4%
ROIC
-144.0%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$118.5m | $427.0m
EBITDA
$-136.7m | $41.0m
EBIT
$-137.7m | $40.4m
Net Income
$-163.9m | $352.6m
Free Cash Flow
$-121.3m
Growth (TTM | estimate)
Revenue
- | 909.9%
EBITDA
-90.4% | 126.7%
EBIT
-89.8% | 126.1%
Net Income
-158.5% | 303.3%
Free Cash Flow
-108.8%
Margin (TTM | estimate)
Gross
95.0%
EBITDA
-115.3% | 9.6%
EBIT
-116.2%
Net
-138.3% | 82.6%
Free Cash Flow
-102.3%
More
EPS
$-0.3
FCF per Share
$-0.2
Short interest
2.4%
Employees
209
Rev per Employee
$200.0k
Show more

Is Verona Pharma plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

6x Buy
33%
12x Hold
67%

Analyst Opinions

18 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy
33%
Hold
67%

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
119 119
-
100%
- Direct Costs 5.99 5.99
-
5%
113 113
-
95%
- Selling and Administrative Expenses 198 198
224% 224%
167%
- Research and Development Expense 52 52
247% 247%
44%
-137 -137
90% 90%
-115%
- Depreciation and Amortization 1.09 1.09
40% 40%
1%
EBIT (Operating Income) EBIT -138 -138
90% 90%
-116%
Net Profit -164 -164
158% 158%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about Verona Pharma plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verona Pharma plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
7 days ago
LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its share...
Neutral
GlobeNewsWire
16 days ago
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population
Positive
The Motley Fool
2 months ago
Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking individual stocks: Your returns can be massive and life-changing.
More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO David Zaccardelli
Employees 209
Founded 2005
Website www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today